Riemser Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Riemser Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10815
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Riemser Pharma GmbH (Riemser), formerly Riemser Arzneimittel AG is a distributor of lifecycle management products. The company offers analgesics products, cardiovascular products, over-the-counter medicines, prescription drugs and dental products. It provides medical products for the treatment of infectious diseases, obesity, rheumatology, tuberculosis therapy, neurology, oncology and dermatological disorders such as psoriasis, acromycosis, acne, and herpes. Riemser also offers nutritional supplements. The company has research and development alliances with research institutes, universities, colleges and hospitals across Europe. It has operations in Germany, France and the UK. Riemser is headquartered in Greifswald, Germany.

Riemser Pharma GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Riemser Pharma Acquires European Rights to Prialt from Eisai 12
Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14
Private Equity 15
Ardian May Sell Riemser Pharma for USD494.3 Million 15
AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17
Asset Transactions 19
Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19
Acquisition 20
Riemser Pharma to Acquire Intrapharm Labs 20
Riemser Pharma Acquires Keocyt 21
Riemser Arzneimittel To Acquire 49% Stake In anwerina 22
Riemser Pharma GmbH – Key Competitors 23
Riemser Pharma GmbH – Key Employees 24
Riemser Pharma GmbH – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Riemser Pharma Acquires European Rights to Prialt from Eisai 12
Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14
Ardian May Sell Riemser Pharma for USD494.3 Million 15
AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17
Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19
Riemser Pharma to Acquire Intrapharm Labs 20
Riemser Pharma Acquires Keocyt 21
Riemser Arzneimittel To Acquire 49% Stake In anwerina 22
Riemser Pharma GmbH, Key Competitors 23
Riemser Pharma GmbH, Key Employees 24
Riemser Pharma GmbH, Other Locations 25
Riemser Pharma GmbH, Subsidiaries 25

List of Figures
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Riemser Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Akashi Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Akashi Therapeutics Inc (Akashi Therapeutics), formerly DART Therapeutics Inc is a clinical stage biopharmaceutical company develops treatment for duchenne muscular dystrophy (DMD) and other rare pediatric diseases. The company provides pipeline portfolio such as HT-100, a small molecule dru …
  • Exorka GmbH:企業の戦略的SWOT分析
    Exorka GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Ecron Acunova-製薬・医療分野:企業M&A・提携分析
    Summary Ecron Acunova (EA), a subsidiary of Take Solutions Ltd. is a clinical research organization (CRO) serving big pharma companies locally. It offers clinical trial management, clinical data management services. Its services include bioavailability and bioequivalence services, Phase I to IV clin …
  • Harmonic Inc (HLIT):企業の財務・戦略的SWOT分析
    Harmonic Inc (HLIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The Wendy’s Company:戦略・SWOT・企業財務分析
    The Wendy’s Company - Strategy, SWOT and Corporate Finance Report Summary The Wendy’s Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Coolgardie Minerals Ltd (CM1):企業の財務・戦略的SWOT分析
    Coolgardie Minerals Ltd (CM1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Stanwell Corp Ltd:企業の戦略的SWOT分析
    Stanwell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • MicroPort Scientific Corp (853):医療機器:M&Aディール及び事業提携情報
    Summary MicroPort Scientific Corp (MicroPort) a subsidiary of Otsuka Medical Devices Co Ltd is a medical device company which develops, manufactures and markets cardiovascular treatment devices. The company provides products such as cardiovascular devices, orthopedic devices, endovascular devices, e …
  • PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • Bechtel Corp:企業の戦略的SWOT分析
    Bechtel Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • MPI Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary MPI Research Inc (MPI) is a contract research company that provides preclinical and early clinical research services. The company’s services comprise drug safety services, discovery sciences solutions, bioanalytical and analytical solutions, surgical services, medical device evaluation, tran …
  • Anadarko Petroleum Corp (APC):企業の財務・戦略的SWOT分析
    Anadarko Petroleum Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Inova Health System:製薬・医療:M&Aディール及び事業提携情報
    Summary Inova Health System (Inova) is a non-profit health care system operating through multiple hospitals. It offers home health and long term care services, joint replacement services, liver disease services, mental health services, and neurosciences services among others. Through a network of ho …
  • The McClatchy Company:企業の戦略・SWOT・財務分析
    The McClatchy Company - Strategy, SWOT and Corporate Finance Report Summary The McClatchy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Targovax ASA (TRVX):企業の財務・戦略的SWOT分析
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline …
  • RPC Astrapak:企業の戦略的SWOT分析
    RPC Astrapak - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GAIL (India) Ltd (GAIL)
    GAIL (India) Ltd (GAIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • PZ Cussons Nigeria Plc:企業の戦略・SWOT・財務情報
    PZ Cussons Nigeria Plc - Strategy, SWOT and Corporate Finance Report Summary PZ Cussons Nigeria Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • IndigoVision Group plc (IND):企業の財務・戦略的SWOT分析
    Summary IndigoVision Group plc (IndigoVision) is a developer, manufacturer and distributor of end-to-end IP security management systems. The company’s products include management software, cameras and encoders, specialized cameras, body worn video, integration and recorders. Its camera and encoder’s …
  • Inova Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Inova Diagnostics Inc (Inova), a subsidiary of Werfen Life Group SAU is a medical device company that develops and commercializes new autoimmune technologies and diagnostic markers. The company's diagnostic reagent products include QUANTA Flash used for semi-quantitative determination of aut …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆